Bridging Study of L059 (Levetiracetam) in Patients With Epilepsy by Double Blind Method

Double-blind, randomized, placebo-controlled, multi center trial to evaluate the efficacy and safety of levetiracetam as adjunctive treatment in adult Japanese epileptic subjects with partial onset seizures...

Date First Received: January 14, 2008

Last Updated: March 7, 2008

Verified by: UCB, March 2008

Clinical Trial Phase: Phase 2 | Start Date: January 2001

Overall Status: Completed

Estimated Enrollment: 216

Brief Summary

Official Title: “Bridging Study of L059(Levetiracetam) in Patients With Epilepsy by Double Blind Method”

Condition Keyword(s):

Intervention(s):

Double-blind, randomized, placebo-controlled, multi center trial to evaluate the efficacy and safety of levetiracetam as adjunctive treatment in adult Japanese epileptic subjects with partial onset seizures.

Study Type: Interventional

Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: July 2003

Intervention(s) in this Clinical Trial

  • Drug: Levetiracetam

Outcome Measures for this Clinical Trial

Primary Measures

  • partial onset siezure frequency per week
    • Time Frame: collection of seizure count throughout the whole study (baseline and treatment periods)

Secondary Measures

  • safety and tolerability
    • Time Frame: safety and tolerability data were collected throughout the study period

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • simple and/or complex partial seizures with or without secondary generalization, and first partial seizure >= 2 years before selection visit;
  • seizures classifiable according to the ILAE classification;
  • minimum of 12 partial seizures per 12 weeks with a minimum of two partial seizures per 4 weeks from the selection visit to the end of the baseline period ;
  • exposed to two or more standard AEDs;
  • taking up to three of the standard AEDs, at the initiation of the trial.

Exclusion Criteria:

  • medication influencing the CNS, except for medication taken for antiepileptic treatment;
  • partial seizures uncountable due to clustering, including status epilepticus, during the 3 months prior to the selection visit;
  • history of cerebrovascular disease including transient ischemic attack (TIA) and progressive cerebral disorder or progressive neurological disorder;
  • presence or history of any clinically significant allergic condition and complication or history of significant alcohol abuse or drug abuse in the past.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 16 Years

Maximum Age for this Clinical Trial: 65 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: UCB

Overall Clinical Trial Officials and Contacts

UCB Clinical Trial Call Center Study Director +1 877 822 9493 (UCB)  

Additional Information

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00600509

Study ID Number: N165

ClinicalTrials.gov Identifier: NCT00600509

Health Authority: Japan: Ministry of Health, Labor and Welfare

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.